Cerus (CERS) Rating Increased to Sell at BidaskClub
Cerus (NASDAQ:CERS) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
Several other brokerages also recently issued reports on CERS. Robert W. Baird restated a “buy” rating and issued a $5.00 price objective on shares of Cerus in a research report on Friday, December 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Cerus in a research report on Friday. ValuEngine upgraded Cerus from a “strong sell” rating to a “sell” rating in a research report on Thursday. BTIG Research restated a “neutral” rating on shares of Cerus in a research report on Friday, December 8th. Finally, Zacks Investment Research downgraded Cerus from a “buy” rating to a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Cerus has a consensus rating of “Hold” and an average target price of $6.17.
Cerus (CERS) traded up $0.12 on Friday, reaching $3.84. The company’s stock had a trading volume of 673,678 shares, compared to its average volume of 590,531. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71. The stock has a market capitalization of $438.09, a P/E ratio of -6.51 and a beta of 1.93. Cerus has a one year low of $1.93 and a one year high of $4.70.
Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. Cerus’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.14) earnings per share. equities analysts anticipate that Cerus will post -0.57 EPS for the current fiscal year.
Several large investors have recently modified their holdings of CERS. Elk Creek Partners LLC increased its stake in Cerus by 32.3% in the second quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock valued at $14,406,000 after purchasing an additional 1,402,106 shares during the last quarter. Ark Investment Management LLC increased its stake in Cerus by 126.5% in the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock valued at $4,219,000 after purchasing an additional 938,647 shares during the last quarter. First Midwest Bank Trust Division increased its stake in Cerus by 50.3% in the third quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock valued at $2,944,000 after purchasing an additional 360,785 shares during the last quarter. Vanguard Group Inc. increased its stake in Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after purchasing an additional 184,076 shares during the last quarter. Finally, Premier Asset Management LLC acquired a new position in Cerus in the third quarter valued at $348,000. Institutional investors and hedge funds own 56.44% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/cerus-cers-rating-increased-to-sell-at-bidaskclub/1797979.html.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with Analyst Ratings Network's FREE daily email newsletter.